Skip to content Skip to footer
Subscribe Now
INSIGHTS+

New Drug Designations – May 2025  

Shots:      PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, Health Canada and NMPA    The May 2025 report covers designations granted to 44 drugs and 5 medical devices, spanning 15 small molecules, 7 biologics, 13 cell and gene therapies & 5 medical devices among others   …
June 24, 2025

Read more

THOUGHTSPOT

Precision Medicine in Cancer Treatment: Revolutionizing Patient Care Through Personalized Approaches

Precision medicine has emerged as a transformative approach in cancer treatment, moving away from the traditional one-size-fits-all methodology toward highly individualized therapeutic strategies. This paradigm shift recognizes that each patient's cancer is unique, with distinct genetic profiles, molecular characteristics, and treatment responses that require tailored approaches. By leveraging advanced genomic technologies, biomarker identification, and sophisticated…
June 24, 2025

Read more

Enhancing Hematologic Care: Lorah Perlee from Regeneron in a Riveting Dialogue Exchange with PharmaShots
VIEWPOINTS

Enhancing Hematologic Care: Lorah Perlee from Regeneron in a Riveting Dialogue Exchange with PharmaShots

Shots:  At ASH 2024, Regeneron shared data from the P-III exploratory cohort investigating the pozelimab and cemdisiran combination (poze-cemdi) in patients with paroxysmal nocturnal hemoglobinuria  The novel combination (poze-cemdi) achieved meaningful control of intravascular hemolysis compared to ravulizumab   PharmaShots welcomes Lorah Perlee, Vice President, Global Program Head, Hematology and Translational Sciences at Regeneron, for an…
June 23, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Jun 16, 2025 – Jun 20, 2025)   

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilar, Animal Health & DigiHealth. Check out our full report below:    Johnson & Johnson Reports P-II (RedirecTT-1) Trial Data on Talvey + Tecvayli for R/R Multiple Myeloma  Read More: J&J  Camurus Reports Topline P-IIb (POSITANO) Trial Data on CAM2029 for…
June 20, 2025

Read more

TOP 20

Top 20 Nutraceutical Companies of 2025

Shots:  Nutraceuticals offer significant health benefits by enhancing body function and supporting body repair and growth  In 2024, the global nutraceuticals market is valued at $458.55B and is projected to rise to $986.85B by 2032, growing at a CAGR of 10.18%. Nestlé leads the market with reported segment revenue of $16.75B, followed by Danone and…
June 19, 2025

Read more

VIEWPOINTS

Patient Characteristics Trends in CAR-T Therapies: Dr. Ira Zackon in a Stimulating Discussion with PharmaShots 

Shots:  In a retrospective study sourced from EHR data for DLBCL patients, groundbreaking insights were unearthed that could potentially shape the treatment landscape of CAR-T Therapies in DLBCL  Data from the 10-year study is divided into pre- and post-CAR-T eras to better reflect trends in patient demographics and disease progression  PharmaShots welcomes Dr. Ira Zackon,…
June 18, 2025

Read more

VIEWPOINTS

Standardizing DLBCL Treatment: Dr. John Burke in a Riveting Conversation with PharmaShots  

Shots:   In the five-year follow-up data from the randomized POLARIX study, where participants received R-CHOP with a placebo for polatuzumab (control arm) and Pola-R-CHP with a placebo for vincristine   The primary endpoint of the study was progression free survival, and the secondary endpoint was overall survival  PharmaShots welcomes Dr. John Burke from Rocky Mountain Cancer…
June 16, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Jun 09, 2025 – Jun 13, 2025)  

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilar & Animal Health. Check out our full report below:   Apellis Pharmaceuticals and Sobi Report P-III (VALIANT) Trial Data of Empaveli for C3 Glomerulopathy (C3G) and Primary IC-MPGN  Read More: Apellis Pharmaceuticals and Sobi  Daiichi Sankyo Reports First Patient…
June 13, 2025

Read more

MAGAZINE

PharmaShots Magazine-June-2025 Edition

Decentralized Clinical Trials (DCTs) colloquially known as hybrid trials were popularized during COVID-19. With the changing healthcare landscape, trial sponsors are looking for practices that are feasible and cost-effective. DCTs offer holistic solutions to mitigate the gaps in traditional clinical trial models by integrating emerging technologies and gadgets into the nuanced aspects of data capturing.…
June 12, 2025

Read more

Load more